BioTelemetry (BEAT) : Sio Capital Management scooped up 221,894 additional shares in BioTelemetry during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 413,649 shares of BioTelemetry which is valued at $8,632,855.BioTelemetry makes up approximately 3.87% of Sio Capital Management’s portfolio.
Other Hedge Funds, Including , First Light Asset Management added BEAT to its portfolio by purchasing 364,978 company shares during the most recent quarter which is valued at $7,617,091. BioTelemetry makes up approx 3.34% of First Light Asset Management’s portfolio.Trexquant Investment Lp reduced its stake in BEAT by selling 20,555 shares or 57.26% in the most recent quarter. The Hedge Fund company now holds 15,340 shares of BEAT which is valued at $320,146. BioTelemetry makes up approx 0.04% of Trexquant Investment Lp’s portfolio.Alambic Investment Management boosted its stake in BEAT in the latest quarter, The investment management firm added 18,405 additional shares and now holds a total of 46,705 shares of BioTelemetry which is valued at $976,602. BioTelemetry makes up approx 0.22% of Alambic Investment Management’s portfolio.Cadence Capital Management reduced its stake in BEAT by selling 11,423 shares or 18.57% in the most recent quarter. The Hedge Fund company now holds 50,096 shares of BEAT which is valued at $1,038,490. BioTelemetry makes up approx 0.08% of Cadence Capital Management’s portfolio.Kalmar Investments Inc De reduced its stake in BEAT by selling 9,698 shares or 2.43% in the most recent quarter. The Hedge Fund company now holds 389,173 shares of BEAT which is valued at $7,402,070. BioTelemetry makes up approx 0.32% of Kalmar Investments Inc De’s portfolio.
BioTelemetry opened for trading at $18.58 and hit $18.88 on the upside on Thursday, eventually ending the session at $18.7, with a gain of 1.25% or 0.23 points. The heightened volatility saw the trading volume jump to 3,22,123 shares. Company has a market cap of $524 M.
On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.17. The company had revenue of $52.68 million for the quarter, compared to analysts expectations of $50.27 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS.
Many Wall Street Analysts have commented on BioTelemetry. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $20 .